ArticleClinical case reports2025
Immune Checkpoint Inhibitors and Liver Transplantation: Case Report and Review of the Literature.
Article in Clinical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As immunotherapy is becoming more inevitable in everyday oncology, we are witnessing a higher number of patients who are on immunosuppressive medication but are also candidates for immune checkpoint inhibitors (ICIs) treatment. There have been few case reports and several small retrospective studies investigating the use of ICIs in liver transplant recipients mainly with hepatocellular carcinoma and skin cancer, but there is no report regarding the use of atezolizumab for the treatment of metastatic breast cancer in liver transplant recipients. We are presenting a metastatic breast cancer female patient undergoing both immunosuppressive treatment after liver transplantation due to cryptogenic liver failure and anti-programmed death ligand 1 (PDL1) medication-atezolizumab whose liver enzymes and tacrolimus level we have monitored intensively through 18 months and is still ongoing. Our patient has not presented with any signs of acute graft rejection and has a regression on follow-up imaging despite the treatment combination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.